Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | POLQ | O75417 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22585839 | 1.00 | CHEK1 (0.43) | CHEK1CHEK2OPRK1LRRK2IRAK4 | |
| SCHEMBL21724833 | 0.93 | OPRK1 (0.46) | CHEK1CHEK2OPRK1LRRK2IRAK4 | |
| SCHEMBL30201761 | 0.93 | OPRK1 (0.46) | CHEK1CHEK2OPRK1LRRK2IRAK4 | |
| SCHEMBL21765581 | 0.89 | PDE4B (0.51) | OPRK1IRAK4 | |
| SCHEMBL22553657 | 0.88 | IRAK4 (0.42) | LRRK2IRAK4HSD11B1 | |
| SCHEMBL22585840 | 0.88 | IRAK4 (0.42) | LRRK2IRAK4HSD11B1 | |
| SCHEMBL4406630 | 0.86 | CHEK1 (0.47) | CHEK1CHEK2OPRK1IRAK4 | |
| SCHEMBL31678736 | 0.86 | MAPK3 (0.48) | IRAK4 | |
| SCHEMBL31678648 | 0.86 | MAPK3 (0.48) | IRAK4 | |
| SCHEMBL15688851 | 0.84 | YAP1 (0.48) | CHEK1CHEK2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114007697-A | Antiproliferative agents for the treatment of PAH | 辉瑞公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203594-B2 | Anti-proliferative agents for treating PAH | EDNRB, EDNRA, PAH | CHEK1 1238/4885CHEK2 1386/4885OPRK1 4108/4885 |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | EDNRB, EDNRA, PAH | CHEK1 1238/4885CHEK2 1386/4885OPRK1 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.